

Prevention & Treatment of Hepatitis and Chronic Liver Disease

St. Louis, MO September 30, 2023

Conference Location	Renaissance St Louis Airport 801 Natural Bridge Road, Sr, Louis, MO 63134	Phone: (314)429-1100 https://www.marriott.com/en-us/hotels/stlsa-renaissance-st-louis-airport-hotel/overview/
----------------------------	--	--

Parking at the Conference	Complimentary Self-Parking has been arranged for all participants.
	Please bring your parking ticket to the seminar registration desk to receive this rate.

Driving Directions	From Downtown St Louis – <ul style="list-style-type: none"> Take I-64 W/US-40 W Follow signs for Interstate 270 N/Chicago and merge onto I-270 N Take Exit 16 for Page Avenue toward Missouri D Use the left lane to merge onto State Hwy D Use the 2nd from the right lane to take the Lackland Rd exit toward West Port Plaza Turn Left at Westline Industrial Drive. In ¼ mile, the hotel will be on the right.
---------------------------	---

Seminar Agenda and Syllabus Information	Registration begins at 7:30 a.m. in the Orly Room. The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi is available without charge.
--	--

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:30 am	Registration and View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	Review of Viral Hepatitis –HCV <ul style="list-style-type: none"> Highlight of Pre-Lecture 1 Screening and Treatment of HCV Clinical Cases and Discussion
9:00 am	Hepatitis B: Epidemiology, Natural History and Treatment <ul style="list-style-type: none"> The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination Anti-viral therapies of HBV The growing relationship between HBV and HDV
9:30 am	Product Theater # 1 Break and View exhibits
10:15 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> Worldwide perspective and promising research studies Real world outcome studies on HDV and HEV
10:45 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> A review of Pre-course lecture on end-stage liver disease Clinical cases to illustrate HE and Thrombocytopenia

11:15 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery •
11:45 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • A case-based approach to HCC treatment • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC
12:15 pm	<i>Luncheon and Product Theater 2</i>
1:00 pm	<i>Dessert and View Exhibits</i>
1:15 pm	Cholestatic Liver Disease: Primary Biliary Cholangitis (PSC) and Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
2:00 pm	Alcohol Associated Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Warning signs and intervention in alcohol-associated hepatitis
2:20 pm	Fluid Management, Ascites and Hepatorenal Syndrome <ul style="list-style-type: none"> • The diagnosis and treatment of ascites • How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome • New and emerging treatment approaches for of HRS
3:00 pm	<i>Break & View Exhibits</i>
3:15 pm	NAFLD and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Fatty Liver Disease • Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:45 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy Drugs in clinical development for NASH
4:20 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:30 pm
Post-program activities	Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Attendance Policies

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1318. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**HANY ELBESHESHY, MD**

Dr. Hany Elbeshbeshy specializes in liver transplant services and treatment of advanced liver diseases, including liver cancer, cirrhosis, and non-alcoholic fatty liver disease (NASH). He also provides pre- and post-liver transplant care in both hospital and clinic settings. Dr. Elbeshbeshy works with other specialists to provide a team approach to liver cancer patients seeking a cure.

Dr Elbeshbeshy received his medical degree from Cairo University, Cairo, Egypt and completed his residency at Atlantic City Medical Center and his post-doctorate fellowship at the University of Medicine and Dentistry of New Jersey.

Dr. Elbeshbeshy is an assistant professor in the Department of Internal Medicine, Division of Gastroenterology and Hepatology, at Saint Louis University School of Medicine

**JASON J. PAN, MD**

Dr. Pan received his medical degree from the Icahn School of Medicine at Mount Sinai. He completed his internal medicine residency at the Scripps Clinic/Scripps Green Hospital, where he was chosen to be the Chief Resident. During his gastroenterology fellowship at Brown University/Rhode Island Hospital, he was also selected to be the Chief Fellow. He then completed a transplant hepatology and advanced liver disease fellowship at the University of Michigan. Dr Pan is an Assistant Professor of Medicine at Washington University St Louis.

His passion for liver disease started in high school and the first years of medical school, volunteering for hepatitis B outreach and screening programs in local Chinese American communities.

**ALEXA FIDER-WHITE, DMSc, PA-C**

Alexa M. Fider-Whyte, PA-C is a board-certified Physician Assistant at Saint Louis University. She received her undergraduate degree from Norfolk State University as a Dozoretz National Institute for Mathematics and Applied Sciences (DNIMAS) scholar. Additionally, she earned her Master of Medical Science and Physician Assistant degree from Saint Louis University in 2004. In 2005, Alexa was awarded a 12 month clinical hepatology fellowship sponsored by the American Association for the Study of Liver Disease (AASLD)

after which she completed an additional 6 months of training in transplant hepatology.

Professionally, she is an associate member of the American Association for the Study of Liver Disease.

Your Seminar Faculty